TrialNature communications2026

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.

Xiaowei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.